BlackRock
SYRE icon

BlackRock’s Spyre Therapeutics SYRE Stock Holding History

BlackRock’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$278M Sell
5,521,221
-880
-0% -$33.2K ﹤0.01% 1470
2025
Q4 		$181M Buy
5,522,101
+1,539,357
+39% +$40.2M ﹤0.01% 1746
2025
Q3 		$66.8M Sell
3,982,744
-24,552
-0.6% -$400K ﹤0.01% 2333
2025
Q2 		$60M Buy
4,007,296
+434,622
+12% +$6.43M ﹤0.01% 2343
2025
Q1 		$57.6M Buy
3,572,674
+173,083
+5% +$3.6M ﹤0.01% 2303
2024
Q4 		$79.1M Buy
3,399,591
+736,444
+28% +$21.6M ﹤0.01% 2210
2024
Q3 		$78.3M Buy
2,663,147
+259,706
+11% +$7.23M ﹤0.01% 2221
2024
Q2 		$56.5M Buy
2,403,441
+1,846,750
+332% +$62.3M ﹤0.01% 2341
2024
Q1 		$21.1M Buy
556,691
+536,929
+2,717% +$15.6M ﹤0.01% 2962
2023
Q4 		$425K Sell
19,762
-6
-0% -$83 ﹤0.01% 4461
2023
Q3 		$242K Sell
19,768
-1,388
-7% -$18.3K ﹤0.01% 4629
2023
Q2 		$238K Sell
21,156
-4,790
-18% -$22.7K ﹤0.01% 4689
2023
Q1 		$188K Buy
25,946
+108
+0.4% +$1.19K ﹤0.01% 4793
2022
Q4 		$291K Sell
25,838
-15,469
-37% -$278K ﹤0.01% 4747
2022
Q3 		$542K Sell
41,307
-1,477
-3% -$18.2K ﹤0.01% 4704
2022
Q2 		$540K Sell
42,784
-74,088
-63% -$2.6M ﹤0.01% 4754
2022
Q1 		$6.72M Sell
116,872
-3,067
-3% -$258K ﹤0.01% 3792
2021
Q4 		$14.2M Buy
119,939
+583
+0.5% +$92K ﹤0.01% 3470
2021
Q3 		$23.7M Sell
119,356
-4,799
-4% -$839K ﹤0.01% 3166
2021
Q2 		$21.6M Sell
124,155
-9,857
-7% -$1.79M ﹤0.01% 3248
2021
Q1 		$26.5M Buy
134,012
+4,413
+3% +$847K ﹤0.01% 3029
2020
Q4 		$25.5M Buy
129,599
+4,488
+4% +$930K ﹤0.01% 2889
2020
Q3 		$22.2M Sell
125,111
-3,562
-3% -$659K ﹤0.01% 2802
2020
Q2 		$29.8M Buy
128,673
+52,314
+69% +$9.96M ﹤0.01% 2587
2020
Q1 		$8.9M Sell
76,359
-530
-0.7% -$90.1K ﹤0.01% 3057
2019
Q4 		$14.7M Buy
76,889
+788
+1% +$155K ﹤0.01% 3052
2019
Q3 		$14.6M Buy
76,101
+1,912
+3% +$372K ﹤0.01% 2997
2019
Q2 		$12.7M Buy
74,189
+14,573
+24% +$2.52M ﹤0.01% 3108
2019
Q1 		$12M Buy
59,616
+7,454
+14% +$1.55M ﹤0.01% 3027
2018
Q4 		$9.77M Buy
52,162
+11,002
+27% +$2.33M ﹤0.01% 3096
2018
Q3 		$9.85M Buy
41,160
+8,260
+25% +$1.93M ﹤0.01% 3241
2018
Q2 		$8.7M Buy
32,900
+31,920
+3,257% +$7.85M ﹤0.01% 3304
2018
Q1 		$243K Buy
980
+102
+12% +$18.4K ﹤0.01% 4172
2017
Q4 		$119K Buy
878
+141
+19% +$17.2K ﹤0.01% 4310
2017
Q3 		$91K Sell
737
-16
-2% -$1.5K ﹤0.01% 4377
2017
Q2 		$72K Buy
753
+147
+24% +$20.3K ﹤0.01% 4463
2017
Q1 		$113K Buy
+606
New +$85.6K ﹤0.01% 4308

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

BlackRock's SYRE Position: Q1 2026 in Review

BlackRock reduced its Spyre Therapeutics (SYRE) stake by 0.02% in Q1 2026, selling an estimated $33.2K and leaving 5,521,221 shares worth $278M. The position accounts for ﹤0.01% of the portfolio, ranked #1470.

BlackRock first reported a position in SYRE in Q1 2017 and has held it in 37 quarters since. 197 funds tracked by Wall St. Rank hold SYRE as of Q1 2026.

  • BlackRock held 5,521,221 shares of Spyre Therapeutics worth $278M as of Q1 2026.
  • BlackRock sold 880 Spyre Therapeutics shares in Q1 2026, an estimated $33.2K.
  • Spyre Therapeutics made up ﹤0.01% of BlackRock's portfolio in Q1 2026, its #1470 holding.
  • BlackRock first reported a position in Spyre Therapeutics in Q1 2017 and has held it in 37 quarters since.
  • 197 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q1 2026.

Based on BlackRock's 13F filing for Q1 2026, filed 13 May 2026.